Labeling
Deep Dive
Labeling violations are the single most common cause of import detentions, Warning Letters, and recall actions across all FDA-regulated product categories. A product can be correctly manufactured, properly registered, and accurately Prior Noticed — and still be refused entry because the net weight is in metric units only, or the ingredient list uses marketing names instead of INCI. This module consolidates the labeling rules that apply across categories: the anatomy of a U.S.-compliant label, net quantity rules, bilingual requirements, claims standards, type size requirements, digital content as labeling, and the top violations consultants encounter in practice.
Label vs. Labeling — The Critical Legal Distinction
FDA makes a fundamental legal distinction between "label" and "labeling" that most people outside the industry don't know exists — and that has enormous practical consequences for compliance.
Label (under 21 U.S.C. § 321(k)): The written, printed, or graphic matter on the immediate container of an article — the physical label stuck to or printed on the product or its packaging.
Labeling (under 21 U.S.C. § 321(m)): All labels AND all other written, printed, or graphic matter upon any article or any of its containers or wrappers, or accompanying such article. This broader definition has been interpreted by courts to include websites, brochures, package inserts, catalogs, and even social media posts that are linked to or associated with the product.
Your Website Is Your Label. Your Instagram Is Your Label.
When your client's Korean beauty brand posts on Instagram "Our serum stimulates collagen production at the cellular level" — that post is labeling under 21 U.S.C. § 321(m). FDA does not need to inspect the physical product to take action. They can cite the URL. Warning Letters routinely include hyperlinks to website pages and social media posts. The FDA inspector reviewing a Prior Notice doesn't look only at the physical label — they search for the company online. A compliant physical label paired with drug claims on a website = an unapproved drug entering the U.S. market.
The Anatomy of a U.S.-Compliant Label
Every FDA-regulated product label has specific panels with specific required content on each. The physical layout is regulated — certain elements must appear on specific panels, in specific locations, with minimum type sizes. Understanding panel terminology is essential because FDA regulations specify requirements by panel name.
• Net quantity in metric only without U.S. equivalent
• Net quantity not in bottom 30% of PDP
• Statement of identity missing (trade name only, no product type)
• Type size for product identity not proportional to PDP area
• Nutrition/Supplement Facts using old pre-2020 format
• Manufacturer address incomplete (no country for foreign manufacturers)
• INCI names incorrect or using common/trade names
• Allergen declaration missing or sesame not included
• "FDA Approved" claim — never allowed for food, cosmetics, supplements
• Country of origin missing for required products
• QR codes linking to non-compliant website content
Net Quantity of Contents — The Most Commonly Wrong Element
The net quantity of contents declaration is required on every FDA-regulated consumer product. It is also, consistently, one of the most commonly violated labeling requirements for international products entering the U.S. The rules are specific and non-negotiable.
The Dual Declaration Requirement
Under 21 CFR § 101.7 and 15 U.S.C. § 1453 (FPLA), all packaged consumer commodities entering U.S. commerce must declare net quantity in both U.S. customary units AND metric units. Neither alone is sufficient.
Net Quantity Placement Rules
- Must appear on the Principal Display Panel — not on the information panel or back of pack
- Must be in the bottom 30% of the PDP area
- Must be in lines generally parallel to the base of the container
- Minimum type size based on PDP area (see type size table below)
- No other information shall appear in the immediate area of the net quantity statement that may render it misleading
Type Size Requirements — Minimum Legibility Standards
FDA and the FPLA specify minimum type sizes for required label elements based on the size of the principal display panel. Falling below these minimums = misbranding. These requirements are frequently violated by international manufacturers who size labels for aesthetics rather than compliance.
Additionally: the statement of identity must be in bold type and must be at least one-half the size of the largest type on the PDP. Trade names cannot be larger than the statement of identity type size.
Language Requirements — English is Mandatory
All required label information must appear in English under 21 CFR § 101.15 (food), 21 CFR § 201.15 (drugs), and corresponding regulations for other categories. A label entirely in a foreign language — regardless of how accurately it communicates the required information — is automatically misbranded if it lacks English text.
The Bilingual Label Rules
- English is required for all mandatory elements — statement of identity, net quantity, ingredient list, directions for use, required warnings, manufacturer name and address, and all required panels
- Additional languages are permitted — a bilingual label in English + Spanish, English + Korean, or English + Arabic is perfectly acceptable
- Foreign language text cannot replace English — even if the foreign text says exactly the same thing, the English version must independently appear
- English text cannot be smaller than foreign language text — if Spanish and English appear on the same label, they must be in equivalent type sizes for required elements
- Voluntary foreign language content on panels other than the Information Panel is generally acceptable as long as it makes no false, misleading, or drug claims
The Bilingual Label Trap for Ethnic Market Products: Products manufactured for ethnic communities in the U.S. (Latin American, Asian, Middle Eastern) are sometimes labeled primarily in a foreign language with small English text — or with English translations so poorly done that the required elements are effectively inaccessible. FDA does not accept this. All required elements must be fully and accurately stated in English, in legible type, in the correct panel locations. A thorough English audit of every label is mandatory before any international brand enters U.S. distribution.
Claims Requirements — Cross-Category Rules
Each product category has specific claims rules covered in depth in the registration modules. This section consolidates the key rules in one place for reference during label reviews.
"Treats diabetes"
"Supports immune health"
Illegal for conventional food
"Reduces appearance of lines"
"High in Vitamin C"
"May reduce risk of heart disease"
Any form of this phrase
Digital Content as Labeling — The Modern Compliance Challenge
The statutory definition of "labeling" — written, printed, or graphic matter accompanying the article — has been extended by courts and FDA policy to cover digital content. This is one of the most important and least understood aspects of modern FDA compliance.
| Digital Content Type | FDA's Position | Practical Consequence |
|---|---|---|
| Company website | Treated as labeling when it promotes specific products. FDA routinely cites URLs in Warning Letters. | Every product claim on every page must comply with the same rules as the physical label. Drug claims on a website = unapproved drug, regardless of what the physical label says. |
| Official social media (company-controlled) | Treated as labeling. Posts from the brand's own accounts — Instagram, TikTok, Facebook, X — are labeling when promoting specific products. | Brand's own posts making drug claims for a supplement = unapproved drug. All official accounts must follow the same claims rules as the label. |
| Amazon / marketplace listings | Treated as labeling when controlled by the brand or distributor. Product descriptions, bullet points, and A+ content are labeling. | Disease claims in Amazon product descriptions = unapproved drug, regardless of physical label. FDA searches Amazon for products making drug claims. |
| QR codes on labels | If a QR code on the physical label links to a webpage, the content of that webpage becomes part of the label's labeling. FDA can follow the QR code. | A compliant label with a QR code linking to a page making drug claims = non-compliant label. Every QR code destination must be audited. |
| Paid influencer posts | FDA treats influencer posts as promotional material. If a brand pays an influencer to make drug claims for a supplement, the brand is responsible for those claims. | Influencer FTC disclosure required + no drug claims. Brand is liable for influencer content they commissioned, regardless of whether a disclaimer is present. |
| Customer testimonials (amplified) | If a brand reposts, amplifies, likes, or shares a customer testimonial making drug claims, FDA may consider the brand to have adopted those claims. | Brands should not amplify customer testimonials containing disease claims. "As seen on" links to news articles making drug claims also count. |
Manufacturer Name and Address — Getting It Right
The manufacturer/distributor name and address requirement applies across all product categories but is implemented slightly differently in each. Here is the consolidated rule set:
Cross-Category Labeling Requirements — The Master Matrix
Use this reference matrix during label reviews to quickly identify what each product category requires. Categories are Food, Drug (Rx), Drug (OTC), Cosmetic (MoCRA), and Dietary Supplement.
Top Labeling Violations — The Consultant's Watchlist
Based on FDA Warning Letters, import refusal records, and recall notices, these are the labeling violations that appear most frequently. Every label review should specifically check for each of these.
The Label Review Workflow — A Practical Process
When a client provides a label for review, follow this systematic process to ensure nothing is missed. Document every finding with a specific CFR citation.
A Vietnamese Functional Beverage — 11 Labeling Deficiencies Found
A Vietnamese company submits labels for a fruit-based functional drink targeting the U.S. market. The product contains added vitamins and herbal extracts. Label review finds the following deficiencies:
- Critical #1: Website says "clinically proven to boost immune system and fight viral infections" — disease claim converts product to unapproved drug. Must remove before ANY shipment.
- Critical #2: Label entirely in Vietnamese with no English text — automatic misbranding.
- Major #3: Net quantity shows "500ml" only — missing fluid oz equivalent. Correct: "16.9 FL OZ (500 mL)"
- Major #4: Nutrition Facts panel uses pre-2020 format — "Calories from Fat" present, "Added Sugars" missing, serving size uses old RACC.
- Major #5: Ingredient list contains "Natural Flavor" which is acceptable, but also "FD&C Red No. 6" — a color not approved for use in beverages in the U.S. Product is adulterated.
- Major #6: No allergen declaration — product contains soybeans. Missing allergen declaration triggers misbranding AND constitutes a serious safety issue.
- Major #7: Net quantity not in the bottom 30% of PDP — appears in upper right corner.
- Minor #8: Manufacturer address shows city and country but no street address or postal code.
- Minor #9: Statement of identity type size smaller than required minimum for the PDP area.
- Minor #10: "Contains natural antioxidants" — acceptable as factual statement but needs review given website disease claims context.
- Minor #11: QR code on back panel links to Vietnamese-language website with no English translation.
Items 1, 5, and 6 are blocking issues — the product cannot enter U.S. commerce in its current form regardless of other corrections. Items 2–4 and 7 prevent import without a total label redesign. Items 8–11 can be corrected in the label revision without reformulation.
- "Label" and "labeling" are different legal terms. Labeling is broader — it includes the physical label, any written material accompanying the product, the company website, official social media accounts, marketplace listings, and QR code destinations. Drug claims anywhere in the labeling chain convert the product to an unapproved new drug.
- Net quantity is the most commonly wrong element on international product labels. It must appear in the bottom 30% of the Principal Display Panel, in both U.S. customary units AND metric units, at minimum type size based on PDP area. Metric-only declarations are misbranding.
- English is mandatory for all required label elements across all categories. Additional languages are permitted but cannot replace English. The English text must be at least as large as corresponding foreign language text for required elements.
- The Master Labeling Matrix shows at a glance what each category requires. Key differences: Nutrition Facts (food) vs. Drug Facts (OTC drug) vs. Supplement Facts (dietary supplement) vs. INCI ingredient list (cosmetic). NDC numbers required only for drugs. DSHEA disclaimer required only for supplements. UDI required only for devices.
- The top labeling violations are: metric-only net quantity, old Nutrition Facts format, undeclared sesame allergen, non-INCI cosmetic ingredient names, drug claims in digital content, foreign-language-only labels, missing DSHEA disclaimer or NDC, "FDA Approved" claims, and unapproved color additives.
- A systematic label review workflow — product classification first, then PDP audit, information panel audit, special elements audit, digital content audit, and documented findings report — is the most practical and legally defensible way to deliver label review services. Document every finding with the specific CFR citation and required correction.
- A QR code on a product label makes the QR code destination part of the product's labeling. Every QR code on every client label must be audited for compliance — not just the printed label surface.
Need a professional label review before your first U.S. shipment?
Regovant provides comprehensive label review reports covering all required elements, CFR citations, and a designer correction brief for every deficiency found. Preventing one detained shipment pays for many label reviews.